Lu Af35700
Treatment-resistant Schizophrenia
H. Lundbeck A/SPhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 89/ 100
Competitive context
20 Active assets in the Treatment-resistant Schizophrenia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Olanzapine Dr. Stavroula Rakitzi | Phase 4 | BB |
Risperdal Dr. Stavroula Rakitzi | Phase 4 | BB |
AMISULPRIDE University of California, Los Angeles | Phase 4 | BB |
Clozapine Dr. Stavroula Rakitzi | Phase 4 | BB |
Dextromethorphan All India Institute of Medical Sciences, Bhubaneswar | Phase 4 | BB |
View all 23 →
Same molecule, other indications
Lu Af35700 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →